Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial

[1]  J. Berkhof,et al.  Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended? , 2015, International journal of cancer.

[2]  R. M. Austin,et al.  Comparison of Cervical Cancer Screening Results Among 256,648 Women in Multiple Clinical Practices , 2015, Cancer cytopathology.

[3]  J. Dillner,et al.  Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial , 2015, International journal of cancer.

[4]  T. Wright,et al.  Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. , 2015, Gynecologic oncology.

[5]  Naveena Singh,et al.  Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study , 2014, BMJ : British Medical Journal.

[6]  M. Schiffman,et al.  Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. , 2014, Journal of the National Cancer Institute.

[7]  J. Cuzick,et al.  A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes , 2014, International journal of cancer.

[8]  K. Hajifathalian,et al.  Co-testing for detection of high-grade cervical intraepithelial neoplasia and cancer compared with cytology alone: a meta-analysis of randomized controlled trials. , 2014, Journal of public health.

[9]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[10]  J. Dillner,et al.  Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial , 2014, BMJ : British Medical Journal.

[11]  C. Wheeler,et al.  Three-Year Risk of Cervical Precancer and Cancer After the Detection of Low-Risk Human Papillomavirus Genotypes Targeted by a Commercial Test , 2014, Obstetrics and gynecology.

[12]  M. von Knebel Doeberitz,et al.  Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS Study , 2013, Journal of the National Cancer Institute.

[13]  H. Cubie,et al.  Understanding HPV tests and their appropriate applications , 2013, Cytopathology : official journal of the British Society for Clinical Cytology.

[14]  M. Hudgens,et al.  Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta‐analysis , 2013, International journal of cancer.

[15]  J. T. Cox,et al.  Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. , 2013, American journal of obstetrics and gynecology.

[16]  D. Taylor,et al.  Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada. , 2013, Vaccine.

[17]  J. Cuzick,et al.  Comparing the performance of six human papillomavirus tests in a screening population , 2013, British Journal of Cancer.

[18]  C. Meijer,et al.  Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape , 2012, BMC Cancer.

[19]  E. Franco,et al.  Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial – the HPV FOCAL Study , 2012, British Journal of Cancer.

[20]  Julian Peto,et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. , 2012, Vaccine.

[21]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012, CA: a cancer journal for clinicians.

[22]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[23]  E. Franco,et al.  A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial) , 2010, BMC Cancer.

[24]  Henry C Kitchener,et al.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. , 2009, The Lancet. Oncology.

[25]  J. Dillner,et al.  Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. , 2009, Journal of the National Cancer Institute.

[26]  S. Wacholder,et al.  Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. , 2008, Journal of the National Cancer Institute.

[27]  J. T. Cox,et al.  An Analysis of High-Risk Human Papillomavirus DNA-Negative Cervical Precancers in the ASCUS-LSIL Triage Study (ALTS) , 2008, Obstetrics and gynecology.

[28]  J. Berkhof,et al.  High-risk HPV type-specific clearance rates in cervical screening , 2007, British Journal of Cancer.

[29]  M Arbyn,et al.  Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis , 2006, The Lancet.

[30]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[31]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[32]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[33]  J. Cuzick,et al.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. , 2012, The Lancet. Oncology.

[34]  Thomas C Wright,et al.  The ATHENA human papillomavirus study: design, methods, and baseline results. , 2012, American journal of obstetrics and gynecology.

[35]  Michael Cunningham,et al.  More than Just the Kappa Coefficient: A Program to Fully Characterize Inter-Rater Reliability between Two Raters , 2009 .

[36]  Hagerstoten.  American society for colposcopy and cervical pathology. , 1999, Journal of lower genital tract disease.